Astera Bio Opportunities Fund LP Q3 2024 Newsletter
Astera delivered a net return of 3.8% for Q3, bringing our year-to-date performance to 7.3%. The quarter began with a strong July (up 5.1%), driven by solid gains in Beam Therapeutics, Avidity Biosciences, and Krystal Biotech. However, these gains were tempered in August (down 1.4%), as positions in Generation Bio, Prime Medicine, and Passage Bio underperformed. September was relatively flat (up 0.1%), with gains f